Anti-human AFP variant monoclonal antibody in radioimmunodetection of primary hepatocellular carcinoma

Table 1 Pre-radioimmunodetection clinical characteristics of hepatocellular carcinoma and control groups

Parameter	HCC group	Control group
		AFP-negative HCC	Liver cirrhosis
Case	11	6	4
Sex, male/female	11/0	6/0	4/0
Median age in years	52	54	54
Age range in years	35-65	35-65	35-65
Tumor mass of ≤ 10 cm	9	6
Tumor mass of > 10 cm	2
AFP of 2000-10000 μg/L	9		0
AFP of > 10000 μg/L	2		0

Table 2 Differences in liver function and Prothrombin time of patients with hepatocellular carcinoma or liver cirrhosis, before and after intravenous injection of 131I-McAb (x ± s)

Group	n	Liver function						Pt, t/s
		TB, cB/μmol·L-1		ALT, lB/nmol·S-1·L-1		A/G		Before	After
		Before	After	Before	After	Before	After
AFP-positive HCC	11	8.1 ± 2.3	8.2 ± 2.1	756 ± 108	748 ± 112	1.4 ± 0.3	1.4 ± 0.2	11.0 ± 2.3	11.0 ± 2.2
AFP-negative HCC	6	6.2 ± 2.0	6.5 ± 2.1	781 ± 116	768 ± 105	1.4 ± 0.2	1.4 ± 0.4	13.0 ± 2.5	13.0 ± 2.6
Liver cirrhosis	4	7.1 ± 2.5	7.5 ± 2.4	914 ± 152	926 ± 146	1.3 ± 0.4	1.3 ± 0.5	12.0 ± 3.1	12.0 ± 3.2

ALT, alanine aminotransferase; HCC, Hepatocellular carcinoma; Pt, Prothrombin time; TB, Total bilirubin.

Table 3 Differences in serum FT3 and FT4, before and after intravenous injection of 131I-McAb (x ± s, cB/pmol•L^-1)

Group	n	FT3		FT4
		Before	After	Before	After
AFP-positive HCC	11	5.2 ± 1.3	5.1 ± 1.2	15.2 ± 3.2	15.1 ± 3.4
AFP-negative HCC	6	5.6 ± 1.5	5.5 ± 1.4	16.2 ± 3.1	16.4 ± 3.0
Liver cirrhosis	4	5.4 ± 1.2	5.3 ± 1.3	15.4 ± 4.5	15.4 ± 4.1

HCC, Hepatocellular carcinoma.

Table 4 Relationship between AFP level and radioimmunoimaging findings of hepatocellular carcinoma patients

AFP, rB/μg·L-1	n	Positive imaging, n	Positive percentage, %
2000-10000	6	6	100
10000-100000	3	2	66.7
> 100000	2	1	50